SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Möller Burkhard)
 

Sökning: WFRF:(Möller Burkhard) > Patient-Reported Ou...

  • Ørnbjerg, Lykke M.Copenhagen University Hospital (författare)

Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care

  • Artikel/kapitelEngelska2024

Förlag, utgivningsår, omfång ...

  • 2024
  • 12 s.

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:347a0403-784e-4c78-97ed-41ada68b000f
  • https://lup.lub.lu.se/record/347a0403-784e-4c78-97ed-41ada68b000fURI
  • https://doi.org/10.3899/jrheum.2023-0764DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:art swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • Objective. To evaluate patient-reported outcomes (PROs) after initiation of tumor necrosis factor inhibitor (TNFi) treatment in European real-world patients with psoriatic arthritis (PsA). Further, to investigate PRO remission rates across treatment courses, registries, disease duration, sex, and age at disease onset. Methods. Visual analog scale or numerical rating scale scores for pain, fatigue, patient global assessment (PtGA), and the Health Assessment Questionnaire–Disability Index (HAQ-DI) from 12,262 patients with PsA initiating a TNFi in 13 registries were pooled. PRO remission rates (pain ≤ 1, fatigue ≤ 2, PtGA ≤ 2, and HAQ-DI ≤ 0.5) were calculated for patients still on the treatment. Results. For the first TNFi, median pain score was reduced by approximately 50%, from 6 to 3, 3, and 2; as were fatigue scores, from 6 to 4, 4, and 3; PtGA scores, from 6 to 3, 3, and 2; and HAQ-DI scores, from 0.9 to 0.5, 0.5, and 0.4 at baseline, 6, 12, and 24 months, respectively. Six-month Lund Efficacy Index (LUNDEX)–adjusted remission rates for pain, fatigue, PtGA, and HAQ-DI scores were 24%, 31%, 36%, and 43% (first TNFi); 14%, 19%, 23%, and 29% (second TNFi); and 9%, 14%, 17%, and 20% (third TNFi), respectively. For biologic-naïve patients with disease duration < 5 years, 6-month LUNDEX-adjusted remission rates for pain, fatigue, PtGA, and HAQ-DI scores were 22%, 28%, 33%, and 42%, respectively. Corresponding rates for patients with disease duration > 10 years were 27%, 32%, 41%, and 43%, respectively. Remission rates were 33%, 40%, 45%, and 56% for men and 17%, 23%, 24%, and 32% for women, respectively. For patients aged < 45 years at diagnosis, 6-month LUNDEX-adjusted remission rate for pain was 29% vs 18% for patients ≥ 45 years. Conclusion. In 12,262 biologic-naïve patients with PsA, 6 months of treatment with a TNFi reduced pain by approximately 50%. Marked differences in PRO remission rates across treatment courses, registries, disease duration, sex, and age at onset of disease were observed, emphasizing the potential influence of factors other than disease activity on PROs.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Rugbjerg, KathrineCopenhagen University Hospital (författare)
  • Georgiadis, StylianosCopenhagen University Hospital (författare)
  • Rasmussen, Simon H.Copenhagen University Hospital (författare)
  • Jacobsson, LennartUniversity of Gothenburg,Sahlgrenska Academy (författare)
  • Loft, Anne G.Aarhus University Hospital (författare)
  • Iannone, FlorenzoUniversity of Bari Aldo Moro (författare)
  • Fagerli, Karen M.Diakonhjemmet Hospital (författare)
  • Vencovsky, JiriCharles University in Prague (författare)
  • Santos, Maria J.Hospital Garcia de Orta (författare)
  • Möller, BurkhardBern University Hospital (författare)
  • Pombo-Suarez, ManuelComplejo Hospitalario Universitario de Santiago (författare)
  • Rotar, ZigaUniversity of Ljubljana,University Medical Centre Ljubljana (författare)
  • Gudbjornsson, BjornNational University Hospital of Iceland (författare)
  • Cefle, AyseKocaeli University (författare)
  • Eklund, KariHelsinki University Central Hospital (författare)
  • Codreanu, CatalinCarol Davila University of Medicine and Pharmacy (författare)
  • Jones, Gareth (författare)
  • van der Sande, MarleenUniversity of Amsterdam (författare)
  • Wallman, Johan K.Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lund Arthritis Research Group (LARG),Forskargrupper vid Lunds universitet,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups,Skåne University Hospital(Swepub:lu)med-jnk (författare)
  • Sebastiani, MarcoUniversity of Modena and Reggio Emilia (författare)
  • Michelsen, BrigitteSørlandet Hospital,Diakonhjemmet Hospital,Copenhagen University Hospital (författare)
  • Závada, JakubCharles University in Prague (författare)
  • Nissen, Michael J.Geneva University Hospital (författare)
  • Sanchez-Piedra, CarlosCarlos III Health Institute (författare)
  • Tomšič, MatijaUniversity Medical Centre Ljubljana,University of Ljubljana (författare)
  • Love, Thorvardur J.University of Iceland (författare)
  • Relas, HeikkiHelsinki University Central Hospital (författare)
  • Mogosan, CorinaCarol Davila University of Medicine and Pharmacy (författare)
  • Hetland, Merete L.Copenhagen University Hospital,University of Copenhagen (författare)
  • Østergaard, MikkelCopenhagen University Hospital,University of Copenhagen (författare)
  • University of GothenburgCopenhagen University Hospital (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of Rheumatology51:4, s. 378-3890315-162X

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy